What it's like to be the only female leader in the room, and how digital innovation is advancing SDoH.

Professor of Medicine and Population Health, The University of Texas at Austin Dell Medical School
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

In the wake of disruption from industries like retail and finance, healthcare incumbents must anticipate disruption from the side or above, not just head-on.

Chief Strategy Officer, BCBS of Massachusetts
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

In this video, Terry Stone discusses where disruptive innovation is likely to come from and why.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

According to Oliver Wyman’s Consumer Survey of US Healthcare, women are more engaged in their health decisions than men. Healthcare companies must give female consumers the kind of health system they're seeking.

Chief Strategy Officer, BCBS of Massachusetts
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Director, Marsh & McLennan Advantage, Healthcare

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Disruption in healthcare will be driven by the power of its trapped – and highly exploitable – value.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

While the Graham-Cassidy bill failed to come to a vote keeping ACA as the law of the land, changes are coming. Here are four ways to react.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Healthcare organizations are working hard to become consumer-centric. To achieve real success, they need to focus on becoming magnetic.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Terry Stone writes in The Hill on the critical need to partner with American businesses during this next phase of health reform.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Senior Partner, Healthcare Reform Leader, Mercer

Insights in your inbox

Subscribe
Load More